Company intelligence / Profile preview
Beijing Dayspring Pharmaceutical Technology
Beijing, Beijing, China
- Ownership
- Private
- Development stage
- Other
01
Overview
CG2001, a small molecule developed by Beijing Dayspring Pharmaceutical Technology, is in Phase II clinical trials for androgenetic alopecia and male pattern alopecia, with multicenter, randomized, double-blind, placebo-controlled studies actively ongoing in China. No published top-line data yet.
- Therapeutic areas
- DermatologyMen's Health
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Beijing Dayspring Pharmaceutical Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Beijing Dayspring Pharmaceutical Technology.